Biocon Biologics ties up with Sandoz for 2 biosimilars

Feb 9, 2024



New Delhi: Biocon BiologicsBiocon subsidiary announces five-year partnership Sandoz The AG has granted it the exclusive right to promote, sell and distribute two biosimilars -Trastuzumab and bevacizumabIn Australia, a company statement said.
Under the agreement, Sandoz will distribute Biocon Biologics' brands, OGIVRI (bTrastuzumab) and ABEVMY (bBevacizumab), and facilitate continued access to these medicines that were previously distributed by another pharmaceutical company to patients in Australia.
trastuzumab Is a biosimilar to Herceptin and bevacizumab is a biosimilar to Avastin.
The agreement is effective from January 1, 2024 and commercialization began from February 1.



Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *